Skip to content
DataLookout
Menu

NCT07673081

Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos

StatusActive, Not Recruiting
PhaseNot specified
SponsorPfizer
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Primary and study completion pushed from Sep 30, 2026 to Jan 31, 2027
  2. Minor Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary and study completion moved earlier from Nov 30, 2026 to Sep 30, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 20, 2026 to Jun 22, 2026
    v2
  3. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
Timeframe: up to 3 years
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
Timeframe: up to 3 years

Secondary (2)

Incidence of RSV-related outcomes
Incidence of All-cause outcomes

Arms and interventions

Vaccinated group

Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna)

Unvaccinated comparator group:

Individuals not yet vaccinated at cohort entry, but otherwise eligible

Sites

1 site in 1 country

  • PfizerNew York, New York, United States